Scancell (LON:SCLP) Trading Down 3.2% - What's Next?

Key Points

• Scancell Holdings plc's stock price declined by 3.2%, trading at GBX 9.69 ($0.13) after hitting a low of GBX 9.60 during mid-day trading.
• Insider Martin Diggle purchased 4,400,000 shares at an average price of GBX 10, indicating insider confidence despite the recent stock price drop.
• Scancell is a clinical stage immunotherapy biotech company focused on developing innovative cancer treatments to address significant unmet medical needs.

Scancell Holdings plc (LON:SCLP - Get Free Report)'s stock price traded down 3.2% on Tuesday . The company traded as low as GBX 9.60 ($0.13) and last traded at GBX 9.69 ($0.13). 1,336,894 shares were traded during trading, an increase of 44% from the average session volume of 925,977 shares. The stock had previously closed at GBX 10 ($0.14).

Scancell Price Performance

The company has a quick ratio of 13.01, a current ratio of 3.42 and a debt-to-equity ratio of -566.79. The firm's fifty day moving average price is GBX 10.15 and its 200-day moving average price is GBX 9.61. The stock has a market cap of £92.09 million, a P/E ratio of -426.63 and a beta of 0.35.

Insider Buying and Selling at Scancell

In other Scancell news, insider Martin Diggle purchased 102,236 shares of Scancell stock in a transaction that occurred on Thursday, August 7th. The shares were bought at an average price of GBX 11 per share, for a total transaction of £11,245.96. Corporate insiders own 15.15% of the company's stock.

Scancell Company Profile

Scancell LSE: SCLP is a clinical stage immunotherapy biotech company developing treatments for significant unmet needs in cancer. We aim to translate our innovation and creativity into increased and durable responses in patients without compromising safety, addressing hard-to-treat cancers. Scancell has developed a pipeline of ‘off-the-shelf' vaccines to induce immune responses and highly tumour specific monoclonal antibodies to redirect immune cells or drugs.